Disclosed are compounds comprising diaromatic substituted compound residues namely the anti-viral (anti-HIV) drug delavirdine covalently attached via a linkage to water-soluble non-peptidic oligomers specifically to poly(ethylene glycol) PEG) oligomers. A compound of the invention when administered by any of a number of administration routes exhibits advantages over non-oligomer modified diaromatic substituted compounds.

Disclosed are compounds comprising diaromatic substituted compound residues, namely the anti-viral (anti-HIV) drug delavirdine, covalently attached via a linkage to water-soluble, non-peptidic oligomers, specifically to poly(ethylene glycol) PEG) oligomers. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over non-oligomer modified diaromatic substituted compounds.

Disclosed are compounds comprising diaromatic substituted compound residues, namely the anti -viral (anti-HIV) drug delavirdine, covalently attached via a linkage to water-soluble, non-peptidic oligomers, specifically to poly(ethylene glycol) (PEG) oligomers. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over non-oligomer modified diaromatic substituted compounds.

The invention refers to the use of Reverse Transcriptase (RT) inhibitor compounds for the preparation of pharmaceutical compositions to counteract the loss of cellular differentiation in tumour and non tumour pathologies said compound being able to bind the hydrophobic pocket on the RT subunit p66. Particularly preferred for such uses are the following compounds: nevirapine efavirenz delavirdine corresponding salts and/or pharmaceutically acceptable derivatives thereof.

The present invention relates to the use of a dioxolane thymine compound according to the chemical structure of Formula (I): where R1 is H an acyl group a C1-C20 alkyl or ether group a phosphate diphosphate triphosphate or phosphodiester group for use in the treatment of HIV infections which exhibit resistance to 3TC and/or AZT. Preferably compounds according to the present invention are combined with at least one anti-HIV agent which inhibits HIV by a mechanism other than through the inhibition...

The invention refers to the use of Reverse Transcriptase (RT) inhibitor compounds for the preparation of pharmaceutical compositions to counteract the loss of cellular differentiation in tumour and non tumour pathologies said compound being able to bind the hydrophobic pocket on the RT subunit p66.Particularly preferred for such uses are the following compounds: nevirapine efavirenz delavirdine corresponding salts and/or pharmaceutically acceptable derivatives thereof.(From US2006166970 A1)